Hofmann MH, Gerlach D, Misale S, Petronczki M, Kraut N. Expanding the reach of precision oncology by drugging All KRAS mutants. Cancer Discov. 2022;12:924–37.
Article CAS PubMed PubMed Central Google Scholar
Khan I, Rhett JM, O’Bryan JP. Therapeutic targeting of RAS: New hope for drugging the “undruggable”. Biochim Biophys Acta Mol Cell Res. 2020;1867:118570.
Article CAS PubMed Google Scholar
Schaber MD, Garsky VM, Boylan D, Hill WS, Scolnick EM, Marshall MS, et al. Ras interaction with the gtpase-activating protein (Gap). Proteins. 1989;6:306–15.
Article CAS PubMed Google Scholar
Lu S, Jang H, Gu S, Zhang J, Nussinov R. Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view. Chem Soc Rev. 2016;45:4929–52.
Article CAS PubMed PubMed Central Google Scholar
Banno K, Yanokura M, Iida M, Masuda K, Aoki D. Carcinogenic mechanisms of endometrial cancer: involvement of genetics and epigenetics. J Obstet Gynaecol Res. 2014;40:1957–67.
Article CAS PubMed Google Scholar
Siqi Li ABCMC. A model for RAS mutation patterns in cancers: finding the sweet spot. Nat Rev Cancer. 2018;18:767–77.
Balmain A, Pragnell IB. Mouse skin carcinomas induced in vivo by chemical carcinogens have a transforming Harvey-ras oncogene. Nature. 1983;303:72–4.
Article CAS PubMed Google Scholar
Sukumar S, Notario V, Martin-Zanca D, Barbacid M. Induction of mammary carcinomas in rats by nitrosomethyl-urea involves the malignant activation of the H-ras-1 locus by single point mutations. Nature. 1983;306:658–61.
Article CAS PubMed Google Scholar
Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable RAS: mission possible? Nat Rev Drug Discov. 2014;13:828–51.
Article CAS PubMed PubMed Central Google Scholar
Canon J, Rex K, Saiki AY, Mohr C, Cooke K, Bagal D, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019;575:217–23.
Article CAS PubMed Google Scholar
Janes MR, Zhang J, Li LS, Hansen R, Peters U, Guo X, et al. Targeting KRAS mutant cancers with a covalent G12C-Specific inhibitor. Cell. 2018;172:578–89.e17.
Article CAS PubMed Google Scholar
Johnson ML, Ou SHI, Barve M, Rybkin II, Papadopoulos KP, Leal TA, et al. Activity and safety of Adagrasib (MRTX849) in patients with colorectal cancer (CRC) and other solid tumors harboring a KRAS G12C mutation. Eur J Cancer. 2020;138:S2.
Jänne PA, Rybkin II, Spira AI, Riely GJ, Papadopoulos KP, Sabari JK, et al. Activity and safety of Adagrasib (MRTX849) in advanced/ metastatic non–small-cell lung cancer (NSCLC) harboring KRAS G12C mutation. Eur J Cancer. 2020;138:S1–2.
Patricelli MP, Janes MR, Li L-S, Hansen R, Peters U, Kessler LV, et al. Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state. Cancer Discov. 2016;6:316–29.
Article CAS PubMed Google Scholar
Lito P, Solomon M, Li LS, Hansen R, Rosen N. Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. Science. 2016;351:604–8.
Article CAS PubMed PubMed Central Google Scholar
Li H-y, Qi W-l, Wang Y-x, Meng L-h. Covalent inhibitor targets KRasG12C: a new paradigm for drugging the undruggable and challenges ahead. Genes Dis. 2021; https://doi.org/10.1016/j.gendis.2021.08.011.
Article PubMed PubMed Central Google Scholar
Lanman BA, Allen JR, Allen JG, Amegadzie AK, Ashton KS, Booker SK, et al. Discovery of a covalent inhibitor of KRAS(G12C) (AMG 510) for the treatment of solid tumors. J Med Chem. 2020;63:52–65.
Article CAS PubMed Google Scholar
Jiao D, Yang S. Overcoming resistance to drugs targeting KRAS mutation. Innovation. 2020;1:100035.
PubMed PubMed Central Google Scholar
Nakajima EC, Drezner N, Li X, Mishra-Kalyani PS, Liu Y, Zhao H, et al. FDA Approval Summary: Sotorasib for KRAS G12C-mutated metastatic NSCLC. Clin Cancer Res. 2022;28:1482–6.
Article CAS PubMed PubMed Central Google Scholar
Ou SI, Janne PA, Leal TA, Rybkin, II, Sabari JK, Barve MA, et al. First-in-human phase I/IB dose-finding study of Adagrasib (MRTX849) in patients with advanced KRAS(G12C) solid tumors (KRYSTAL-1). J Clin Oncol. 2022;40:JCO2102752.
Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378:113–25.
Article CAS PubMed Google Scholar
Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, et al. Alectinib versus Crizotinib in Untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017;377:829–38.
Article CAS PubMed Google Scholar
Ryan MB, Fece de la Cruz F, Phat S, Myers DT, Wong E, Shahzade HA, et al. Vertical pathway inhibition overcomes adaptive feedback resistance to KRAS(G12C) inhibition. Clin Cancer Res. 2020;26:1633–43.
Article CAS PubMed Google Scholar
Amodio V, Yaeger R, Arcella P, Cancelliere C, Lamba S, Lorenzato A, et al. EGFR blockade reverts resistance to KRAS(G12C) inhibition in colorectal cancer. Cancer Discov. 2020;10:1129–39.
Article CAS PubMed PubMed Central Google Scholar
Misale S, Fatherree JP, Cortez E, Li CD, Bilton S, Timonina D, et al. KRAS G12C NSCLC models are sensitive to direct targeting of KRAS in combination with PI3K inhibition. Clin Cancer Res. 2019;25:796–807.
Article CAS PubMed Google Scholar
Xue JY, Zhao Y, Aronowitz J, Mai TT, Vides A, Qeriqi B, et al. Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition. Nature. 2020;577:421–5.
Article CAS PubMed PubMed Central Google Scholar
Awad MM, Liu S, Rybkin II, Arbour KC, Dilly J, Zhu VW, et al. Acquired resistance to KRAS(G12C) inhibition in cancer. N Engl J Med. 2021;384:2382–93.
Article CAS PubMed PubMed Central Google Scholar
Liu XL, Wang BB, Wang Y, Wang YX, Yang CH, Tan C, et al. Unbiased screening reveals that blocking exportin 1 overcomes resistance to PI3Kalpha inhibition in breast cancer. Signal Transduct Target Ther. 2019;4:49.
Article PubMed PubMed Central Google Scholar
Li X, Tong LJ, Ding J, Meng LH. Systematic combination screening reveals synergism between rapamycin and sunitinib against human lung cancer. Cancer Lett. 2014;342:159–66.
Article CAS PubMed Google Scholar
Shi JJ, Chen SM, Guo CL, Li YX, Ding J, Meng LH. The mTOR inhibitor AZD8055 overcomes tamoxifen resistance in breast cancer cells by down-regulating HSPB8. Acta Pharmacol Sin. 2018;39:1338–46.
Article CAS PubMed PubMed Central Google Scholar
Tang J, Wennerberg K, Aittokallio T. What is synergy? The Saariselka agreement revisited. Front Pharmacol. 2015;6:181.
Article PubMed PubMed Central Google Scholar
Ni D, Li X, He X, Zhang H, Zhang J, Lu S. Drugging K-Ras(G12C) through covalent inhibitors: mission possible? Pharmacol Ther. 2019;202:1–17.
Article CAS PubMed Google Scholar
Liu P, Wang Y, Li X. Targeting the untargetable KRAS in cancer therapy. Acta Pharm Sin B. 2019;9:871–9.
Article PubMed PubMed Central Google Scholar
Rodenhuis, S. ras and human tumors. Semin Cancer Biol. 1992;3:241–7.
Rubin SM, Sage J, Skotheim JM. Integrating old and new paradigms of G1/S control. Mol Cell. 2020;80:183–92.
Article CAS PubMed PubMed Central Google Scholar
Molina-Arcas M, Moore C, Rana S, van Maldegem F, Mugarza E, Romero-Clavijo P, et al. Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer. Sci Transl Med. 2019;11:eaaw7999.
Xiang HY, Wang X, Chen YH, Zhang X, Tan C, Wang Y, et al. Identification of methyl (5-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate (CYH33) as an orally bioavailable, highly potent, PI3K alpha inhibitor for the treatment of advanced solid tumors. Eur J Med Chem. 2021;209:112913.
Article CAS PubMed Google Scholar
Adachi Y, Ito K, Hayashi Y, Kimura R, Tan TZ, Yamaguchi R, et al. Epithelial-to-mesenchymal transition is a cause of both intrinsic and acquired resistance to KRAS G12C inhibitor in KRAS G12C-mutant non-small cell lung cancer. Clin Cancer Res. 2020;26:5962–73.
留言 (0)